Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
+0.01 (0.14%)
After Hours: 7.00 0.00 (0.00%)
Nov 27, 1:24PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.90 - 7.22
52 week 4.86 - 11.15
Open 6.93
Vol / Avg. 428,941.00/977,238.00
Mkt cap 488.64M
P/E     -
Div/yield     -
EPS -0.63
Shares 69.81M
Beta 2.00
Inst. own 98%
Nov 17, 2015
Progenics Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 9, 2015
Q3 2015 Progenics Pharmaceuticals Inc Earnings Release
Nov 9, 2015
Q3 2015 Progenics Pharmaceuticals Inc Earnings Call - Webcast
Oct 1, 2015
Progenics Pharmaceuticals Inc Research and Development Day
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -717.34% 9.94%
Operating margin -718.05% 7.59%
EBITD margin - 14.85%
Return on average assets -28.76% 3.20%
Return on average equity -39.78% 4.33%
Employees 57 -
CDP Score - -


777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Patrick Fabbio Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 62
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Senior Vice President - Operations and Portfolio Management
Age: 58
Bio & Compensation  - Reuters
Angelo W. Lovallo Jr., CPA Vice President - Finance, Treasurer
Age: 50
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Karen J. Ferrante M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Michael D. Kishbauch Independent Director
Age: 66
Bio & Compensation  - Reuters
David A. Scheinberg MD., Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters